Catalog No.
Product Name
Application
Product Information
Citations
-
p38/Hsp Activator
Iroxanadine sulfate is a dual activator of p38 kinase and heat shock protein (HSP), functioning as a vasculoprotector. This compound exhibits significant biological activity relevant to vascular health and has potential applications in the study of atherosclerosis and other vascular diseases. Researchers may utilize Iroxanadine sulfate to explore therapeutic strategies aimed at modulating p38 and HSP signaling pathways in various models of vascular pathology. -
HSP90 Inhibitor
HSP90-IN-11 is a potent inhibitor of HSP90, exhibiting strong inhibition of HSP90α activity. This compound demonstrates significant antiproliferative effects in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) cell lines, with IC50 values in the low double-digit nanomolar range. HSP90-IN-11 facilitates the rapid degradation of client proteins such as EGFR and Akt in NSCLC cells and induces a notable accumulation of sub-G1 phase cell populations, highlighting its potential for cancer research applications. -
HSP
p5 Ligand for DnaK and DnaJ is a nonapeptide that specifically targets the heat shock proteins DnaK and DnaJ. This ligand corresponds to the primary binding site of a 23-residue segment within the presequence of mitochondrial aspartate aminotransferase, demonstrating high affinity for these chaperones. Its biological activity supports research in cellular stress responses and protein folding mechanisms, making it valuable for studies on molecular chaperones and their roles in various cellular contexts. -
Hsp90 inhibitor
BX-2819 is a potent inhibitor of Heat Shock Protein 90 (Hsp90) with an IC50 value of 41 nM. This compound effectively inhibits the proliferation of various cancer cell lines and has demonstrated significant antitumor activity in vivo, notably reducing the growth of NCI-N87 and HT-29 tumors in nude mouse models. BX-2819 is a valuable tool for research into cancer biology and potential therapeutic strategies targeting Hsp90. -
Hsp72 Antagonist
A8 peptide is an Hsp72 antagonist that inhibits tumor progression and metastasis. By disrupting the interaction between Hsp72 and TLR2, A8 peptide enhances the sensitivity of cancer cells to apoptosis induced by chemotherapeutic agents, including Cisplatin. This reagent is valuable for research in cancer biology, particularly in exploring mechanisms of drug resistance and metastasis. -
Hsp90a Inhibitor
CH5164840 is a potent inhibitor of the N-terminal domain of Hsp90a, exhibiting a high binding affinity with a Kd value of 0.52 nM. This compound demonstrates significant anti-proliferative effects against various human cancer cell lines, including HCT116 and NCI-N87, with IC50 values of 0.15 μM and 0.066 μM, respectively. Additionally, CH5164840 has an oral bioavailability profile with a half-life of 2.64 hours, indicating its potential for effective antitumor applications in therapeutic settings. -
Hsp90 Inhibitor
HSP90-IN-19 is a potent inhibitor of heat shock protein 90 (Hsp90), identified for its effective inhibitory activity with an IC50 value of 0.27 μM. This compound is relevant for studies investigating viral infections, neurodegenerative diseases, and inflammatory processes. Its ability to modulate cellular stress response pathways makes it a valuable tool in biochemical research and drug development efforts targeting Hsp90. -
Endogenous Metabolite
Palmitic acid calcium is a long-chain saturated fatty acid that functions as an endogenous metabolite. It stimulates the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in mouse granulosa cells, contributing to cellular stress response mechanisms. This compound is essential for establishing cell steatosis models, facilitating research into fatty acid metabolism and related metabolic disorders. -
Hsp70 Binder, Apoptosis Inducer
EV206 is a selective binder to the N-terminal domain of Hsp70, functioning as an apoptosis inducer. It promotes the degradation of Hsp70 through the ubiquitin-proteasome pathway, leading to reduced protein stability and inhibition of cellular growth. EV206 effectively induces apoptotic cell death in non-small cell lung cancer cells, suppresses colony formation, and downregulates markers associated with cancer stem cells. Additionally, it demonstrates anti-tumor activity in H460 xenograft models. This compound serves as a valuable tool for research in non-small cell lung cancer. -
HSP Synthesis Inhibitor
KNK423 is a specific inhibitor of heat shock protein (HSP) synthesis, targeting HSP70. This compound enhances the efficacy of Amphotericin B against resistant strains of Aspergillus terreus by disrupting HSP expression. KNK423 is valuable for research in cancer therapy and bacterial infection mechanisms. -
FKBP51-Hsp90 Interaction Inhibitor
FKBP51-Hsp90-IN-1 is a selective inhibitor targeting the FKBP51-Hsp90 protein-protein interaction, exhibiting an IC50 value of 0.1 μM against FKBP51. This compound is valuable for research into stress-related diseases, Alzheimer's disease, and various metabolic disorders, owing to its ability to modulate protein interactions critical for cellular stress responses and stability. Its specificity makes it a potent tool for elucidating the role of FKBP51 in disease mechanisms. -
HSP90 Inhibitor
HSP90-IN-20 is a potent inhibitor of Heat Shock Protein 90 (HSP90) with an IC50 of ≤10 μM. This compound plays a significant role in cancer research by impeding the function of HSP90, which is critical for the stability and activity of several oncogenic proteins. HSP90-IN-20 can be utilized to investigate the therapeutic potential of HSP90 inhibition in various cancer models. -
Hsp70-targeting Peptide
A17 peptide is an Hsp70-targeting peptide that binds to the ATP-binding domains of Hsp70, specifically inhibiting its chaperone activity. This inhibition enhances the sensitivity of cancer cells to apoptosis induced by chemotherapeutic agents, including Cisplatin. A17 peptide is valuable in anticancer chemotherapy research, particularly in studies related to multiple myeloma and other malignancies. -
HSP70/DnaK Substrate Peptide
HSP70/DnaK substrate peptide is a specific peptide recognized and bound by the HSP70/DnaK molecular chaperone. This substrate peptide is essential for probing the functional mechanisms of HSP70/DnaK, facilitating the investigation of its role in protein folding, stabilization, and stress response pathways. It serves as a valuable tool for research applications focused on understanding molecular chaperone activity and cellular proteostasis. -
HSP90 Inhibitor
Hsp90-IN-17 is a selective inhibitor of Heat Shock Protein 90 (HSP90) that interferes with its chaperone activity. This compound demonstrates significant potential in addressing various proliferative conditions, including cancer and neurodegenerative disorders. Hsp90-IN-17 serves as a valuable tool for research focused on the molecular mechanisms of HSP90 and its role in disease progression and treatment responses. -
HSP90 Inhibitor
Aminohexylgeldanamycin hydrochloride is a potent inhibitor of Heat Shock Protein 90 (HSP90). This Geldanamycin derivative demonstrates significant antiangiogenic and antitumor activities, making it valuable for cancer research. Its ability to modulate HSP90 function provides insights into the molecular mechanisms of tumorigenesis and offers potential therapeutic applications in oncology. -
SIRT2/Hsp70 Inhibitor
YM-08 is a selective inhibitor of SIRT2 and Hsp70, exhibiting an IC50 of 19.9 μM for SIRT2. This compound effectively penetrates the blood-brain barrier, making it a valuable tool for studying neurodegenerative diseases and cellular stress responses. Its dual inhibitory activity allows for investigation into SIRT2 and Hsp70's roles in various biological processes and potential therapeutic applications. -
HSP70 Inhibitor
DMT003096 is a selective inhibitor of HSP70, a heat shock protein that plays a critical role in cellular stress responses. Its upregulation has been associated with various cancers, including breast, lung, colon, and cervical cancer. This compound is valuable for research applications targeting cancer therapies and investigating the role of HSP70 in tumor progression and survival mechanisms. -
Hsp90 Inhibitor
Hsp90-IN-40 is a specific inhibitor targeting the C-terminal domain of heat shock protein 90 (Hsp90). It demonstrates significant antiproliferative activity against breast cancer cell lines SKBr3 and MCF-7, with IC50 values of 2.57 µM and 2.43 µM, respectively. By disrupting the function of Hsp90, Hsp90-IN-40 promotes the degradation of Hsp90-dependent proteins, thereby inhibiting cancer cell growth. This compound is valuable for research applications focusing on breast cancer therapeutics and mechanisms of Hsp90 inhibition. -
HSP90 Inhibitor
STA-1474 is a potent and selective inhibitor of Heat Shock Protein 90 (HSP90), primarily functioning by disrupting its chaperone activities, which are crucial for the stability and function of numerous oncogenic proteins. This compound induces apoptosis in tumor cells and exhibits significant antitumor efficacy in spontaneous canine cancer models, such as osteosarcoma and thyroid carcinoma. STA-1474 is valuable for research on solid tumors, including osteosarcoma and breast cancer, and offers insights into the role of HSP90 in cancer biology. -
Hsp90 Inhibitor
Hsp90-IN-15 is a potent Hsp90 inhibitor that exhibits significant anticancer activity. This compound promotes apoptosis in cancer cells and effectively induces cell cycle arrest at the S phase. Hsp90-IN-15 also reduces the expression levels of Hsp90 in HeLa cells, making it a valuable tool for research into cancer therapies targeting the Hsp90 chaperone pathway. -
HSP90 Inhibitor
Hsp90-IN-38 is a potent inhibitor of heat shock protein 90 (HSP90), displaying a strong binding affinity with a dissociation constant (Kd) of 87 nM. This compound effectively inhibits HSP90 ATPase activity, with an IC50 of 0.13 μM. Biological activity has been demonstrated in various cancer cell lines, including HCT116, MCF-7, SKBr3, K562, and A549, with reported IC50 values of 0.187, 0.072, 0.105, 0.403, and 0.31 μM, respectively. Hsp90-IN-38 serves as a valuable tool for research into cancer biology and HSP90-related pathways. -
Hsp90 Inhibitor
PU-20F is a potent Hsp90 inhibitor characterized by an EC50 value of 6.8 μM. This compound competes with Geldanamycin for binding to Hsp90, effectively regulating the activity of this crucial molecular chaperone. PU-20F promotes the degradation of the oncogenic Her2 tyrosine kinase and has demonstrated the ability to inhibit the proliferation of breast cancer cells. It serves as a valuable tool for research focused on breast cancer biology and therapeutic strategies. -
Hsp90β Inhibitor
KUNB106 is a selective inhibitor of Hsp90β, demonstrating binding affinities (KDs) of 91 nM for Hsp90β and 38 μM for Hsp90α. This compound exhibits notable antiproliferative activity against various cancer cell lines, including MDA-MB-231, A549, and SKOV-3, making it a valuable tool for studying triple negative breast cancer. KUNB106's selective inhibition of Hsp90β highlights its potential in oncology research focused on targeted therapies. -
Hsp90 Inhibitor
PU3 is an Hsp90 inhibitor that targets the conserved ATP/ADP pocket of the Hsp90 protein, competing effectively with geldanamycin and other compounds. This reagent has been shown to induce the degradation of key oncogenic proteins like Her2, subsequently inhibiting breast cancer cell proliferation through mechanisms such as retinoblastoma protein hypophosphorylation, G1 phase cell cycle arrest, and differentiation. PU3 presents a promising avenue for cancer research, particularly in the context of targeted cancer therapies. -
HSP70/SIRT2 Inhibitor
HSP70/SIRT2-IN-2 is a dual inhibitor targeting SIRT2 and HSP70, demonstrating an IC50 of 45.1±5.0 μM for SIRT2. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Its ability to simultaneously inhibit these two proteins positions HSP70/SIRT2-IN-2 as a useful candidate for studies focused on tumor progression and potential therapeutic strategies. -
HSP Inhibitor
BMS-358233 is a small molecule inhibitor targeting heat shock protein 90 (Hsp90). By competing with geldanamycin, BMS-358233 induces the degradation of various proteins, including HER2, leading to the inhibition of breast cancer cell growth. This compound causes hypophosphorylation of the retinoblastoma protein, resulting in G1 phase cell cycle arrest and differentiation. BMS-358233 represents a novel class of synthetic Hsp90 inhibitors, offering potential therapeutic strategies for treating various cancers. -
Hsp90 Inhibitor
Flavokawain 1i is a potent Hsp90 inhibitor, targeting the heat shock protein 90, which plays a critical role in protein folding and stability. This compound demonstrates significant anti-cell proliferation activity, making it a valuable tool in cancer research. Its ability to disrupt Hsp90 function can provide insights into cancer cell growth mechanisms and therapeutic strategies. -
Cathepsin D/HSP90 Inhibitor
Tasiamide B is a potent inhibitor of Cathepsin D and HSP90, derived from the marine cyanobacteria Symploca sp. This linear peptide serves as a valuable scaffold for the development of inhibitors targeting aspartic proteases. Tasiamide B has demonstrated significant efficacy in skin cancer studies by effectively interacting with HSP90, highlighting its potential in cancer research and therapeutic applications. -
HSP90 Inhibitor
17-DMAP-GA is a potent inhibitor of Heat Shock Protein 90 (HSP90), derived from the Geldanamycin structure. This compound disrupts HSP90's chaperone function, leading to cell cycle abnormalities and apoptosis in cancer cells. It is utilized in research to study the role of HSP90 in tumorigenesis and to explore therapeutic strategies in cancer treatment. -
HSPA5 Inhibitor
HM03 trihydrochloride is a selective inhibitor of HSPA5 (Heat shock 70kDa protein 5, also known as Bip or Grp78). It exhibits potent anticancer activity, making it a valuable tool for research in cancer biology. This compound facilitates the exploration of HSPA5's role in cellular stress responses and its implications in tumor progression and treatment resistance. -
Hsp90 Inhibitor
HSP90-IN-32 is a selective inhibitor of the C-terminal domain of heat shock protein 90 (Hsp90). It exhibits significant anti-proliferative effects in various melanoma cell lines, including SKMel173, SKMel103, SKMel19, and A375, with IC50 values of 1.01 μM, 0.782 μM, 0.607 μM, and 1.413 μM, respectively. This compound holds potential for research focused on developing novel anti-cancer therapeutics targeting Hsp90. -
Aha1/Hsp90 Disruptor
KU-177 is an effective disruptor of the Aha1/Hsp90 complex. It inhibits Aha1-driven enhancement of Hsp90-dependent tau aggregation, demonstrating an IC50 of 4.08 μM in disrupting Aha1/Hsp90 interactions without affecting Hsp90's ATPase activity. This compound is applicable in research focused on tauopathies, providing valuable insights into neurodegenerative processes. -
HSP90 Inhibitor
Hsp90-IN-39 is a selective inhibitor of the HSP90α isoform. This compound exhibits significant antiproliferative activity across multiple cancer cell lines, including MCF-7, HCT116, SKBr3, K562, and A549. Hsp90-IN-39 is a valuable tool for cancer research, providing insights into HSP90-related pathways and therapeutic potential in oncology. -
HSP90/MAO-A inhibitor
MAO A/HSP90-IN-2 is a dual inhibitor targeting HSP90 and MAO A, exhibiting IC50 values of 0.016 μM and 4.58 μM, respectively. This compound enhances HSP70 expression while concurrently decreasing HER2, phospho-Akt, and IFN-γ induced PD-L1 levels in GL26 cells. It effectively inhibits the growth of both Temozolomide-sensitive and resistant glioblastoma cells, alongside other cancer types such as colon cancer, leukemia, and non-small cell lung cancer. MAO A/HSP90-IN-2 shows promise in addressing tumor immune evasion, making it a valuable tool for cancer research. -
Hsp90 Inhibitor
Hsp90-IN-44 is a selective Hsp90 inhibitor with an IC50 of 9.8 µM. This compound demonstrates significant inhibitory activity, making it a valuable tool for cancer research. Hsp90-IN-44 can be utilized in studies aimed at understanding Hsp90's role in oncogenesis and evaluating potential therapeutic strategies targeting this chaperone protein. -
HSP90 Antagonist
17-AEP-GA is a selective antagonist of HSP90, demonstrating potent inhibition of glioblastoma cell proliferation, survival, migration, and invasion. This compound is valuable for research applications focused on cancer biology, particularly in elucidating the role of HSP90 in oncogenic processes and therapeutic interventions in glioblastoma. -
HSP90 Inhibitor
HSP90i is a potent inhibitor of the heat shock protein 90 (HSP90), a key molecular chaperone involved in the stabilization and folding of client proteins. This compound demonstrates significant biological activity relevant to cancer research and therapeutic applications, particularly in the development of targeted therapies. HSP90i can also serve as an important intermediate for synthesizing ligand-mediated targeted protein degradation agents, such as dPDL1-4, facilitating advancements in targeted drug delivery systems. -
HSP Inhibitor
STA-2842 is a selective inhibitor of heat shock protein HSP90, demonstrating potential therapeutic effects in the context of autosomal dominant polycystic kidney disease (ADPKD). By modulating signaling pathways activated by mutations in PKD1 or PKD2 genes, STA-2842 effectively reduces renal cyst formation and inhibits kidney growth. In preclinical models, this compound has shown promise in slowing the progression of ADPKD, making it a valuable tool for understanding disease mechanisms and developing targeted interventions. -
HSP Inhibitor
17-GMB-APA-GA is a potent inhibitor of Heat Shock Protein 90 (HSP90), known for its role in protein folding and cellular stress responses. This compound is particularly useful in research focused on latent Toxoplasma gondii infections. Its ability to disrupt HSP90 function presents valuable opportunities for studying therapeutic strategies targeting this essential chaperone in infectious disease contexts. -
Hsp90 Inhibitor
HSP90-IN-14 is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting a dissociation constant (Kd) of 0.26 μM. This compound demonstrates significant antiviral activity against influenza viruses, showing EC50 values of 2.6 μM for A/H3N2, 3.9 μM for A/H1N1, and 17 μM for influenza B in MDCK cell assays. HSP90-IN-14 is a valuable tool for research into Hsp90's role in viral infections and therapeutic interventions. -
Hsp70 Inhibitor
YM-1 tosylate is a stable analog of MKT-077 that functions as an orally active inhibitor of Hsp70. This compound has been shown to induce cell death in HeLa cells, while also up-regulating p53 and p21 protein levels. YM-1 tosylate is valuable for research applications focused on cancer biology and cellular stress responses. -
HSP90 Inhibitor
DDO-6691 is a potent inhibitor of heat shock protein 90 (HSP90), targeting its role in protein folding and stabilization. This compound demonstrates significant antiproliferative activity against various tumor cell lines, particularly HCT-116 colon cancer cells, with an IC50 of 1.08 μM. DDO-6691 also effectively inhibits tumor growth in the HCT-116 xenograft mouse model, highlighting its potential for cancer research and therapeutic applications. -
Combined with Hsp90
AMP-PCP is a potent ATP analogue that selectively binds to the N-terminal domain of Hsp90 with a Kd value of 3.8 μM. This binding promotes the formation of the active homodimeric structure of Hsp90, enhancing its chaperone activity. AMP-PCP is valuable in research applications focused on understanding the molecular mechanisms of Hsp90 modulation and its role in protein folding and stability in various cellular contexts. -
HSP Inhibitor
Monorden diacetate is an effective Hsp90 inhibitor that demonstrates significant potential in the development of new fungicides. By targeting the heat shock protein 90 (HSP90), it disrupts the molecular chaperone activity essential for the stability and function of various client proteins. This compound is valuable for research applications focused on fungal biology and disease management. -
HSP Induction Inhibitor
NSC-134754 is a dehydroemetine derivative that functions as a heat shock protein induction inhibitor. It specifically targets Hsp72 and Hsp27 at the post-transcriptional level, without affecting overall protein synthesis, HSF-1 transcriptional activity, or Hsp mRNA levels. Preclinical studies indicate that NSC-134754 exhibits minimal toxicity while enhancing the sensitivity of cancer cells to proteasome and Hsp90 inhibitors. This reagent is applicable in research involving multiple myeloma, prostate carcinoma, and colon carcinoma. -
HSP
HSP90-IN-12 is a potent inhibitor of Heat Shock Protein 90 (HSP90), a chaperone protein essential for protein folding and stability. This compound exhibits significant anti-proliferative effects across various cancer cell lines, making it a valuable tool in cancer research. HSP90-IN-12 disrupts the regulation of HSP90-related proteins and effectively inhibits the HSP90-mediated refolding of luciferase in vitro, highlighting its potential for studying HSP90 dynamics and therapeutic applications in oncology. -
HSP90 Inhibitor
MPC-0767 is a selective and potent inhibitor of heat shock protein 90 (HSP90). As an L-alanine ester proagent of MPC-3100, it exhibits enhanced chemical stability, making it suitable for in vivo applications. MPC-0767 is primarily utilized in research applications focused on cancer biology, as it disrupts the chaperone function of HSP90 and thereby influences the stability of various oncogenic client proteins. -
Hsp90-TPR2A Interaction Inhibitor
Hsp90-IN-43 is a potent inhibitor of the Hsp90-TPR2A interaction, exhibiting an IC50 value of 360 nM and a Kd of 928 nM. This compound effectively inhibits the proliferation of BT474 breast cancer cells, making it a valuable tool for research in breast cancer biology. Its specific activity allows for deeper investigation into the role of Hsp90 in cancer progression and therapeutic response. -
Dye Tethered Hsp90 Inhibitor
HS-131 is a dye-tethered inhibitor that targets heat shock protein 90 (Hsp90). This compound exhibits the ability to selectively bind to and inhibit Hsp90, facilitating the detection of oncogene-driven breast cancers across various molecular subtypes. HS-131 is a valuable research tool for studying the role of Hsp90 in cancer biology and for developing novel therapeutic strategies targeting breast cancer.
